KarunaNews Story

Imagine a groundbreaking "one-product-fits-all" immunotherapy that brings fresh hope to pancreatic cancer patients. UCLA scientists have engineered a therapy using CAR-NKT cells that can relentlessly track and annihilate tumors, even when they've spread to distant organs. "We're essentially surrounding the tumor with no escape routes," asserts Dr. Yanruide (Charlie) Li, ensuring the cancer has nowhere to hide. Unlike traditional methods that cost thousands and take weeks, this ready-to-use solution costs about $5,000 per dose. In tests, these cells demonstrated an uncanny ability to infiltrate even the toughest barriers, proving their mettle in rigorous models of pancreatic cancer. While the therapy's potential spans various cancers, including breast and ovarian, the core mission remains clear: "Pancreatic cancer patients need better treatment options now," emphasizes Dr. Lili Yang. With preclinical trials complete, the team races toward FDA approval, promising a new era in cancer treatment.